Show simple item record

dc.contributor.authorKissling, Esther
dc.contributor.authorPozo, Francisco 
dc.contributor.authorBuda, Silke
dc.contributor.authorVilcu, Ana-Maria
dc.contributor.authorGherasim, Alin 
dc.contributor.authorBrytting, Mia
dc.contributor.authorDomegan, Lisa
dc.contributor.authorGómez, Verónica
dc.contributor.authorMeijer, Adam
dc.contributor.authorLazar, Mihaela
dc.contributor.authorVučina, Vesna Višekruna
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorvan der Werf, Sylvie
dc.contributor.authorLarrauri, Amparo 
dc.contributor.authorEnkirch, Theresa
dc.contributor.authorO'Donnell, Joan
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorHooiveld, Mariëtte
dc.contributor.authorPetrović, Goranka
dc.contributor.authorStoian, Elena
dc.contributor.authorPenttinen, Pasi
dc.contributor.authorValenciano, Marta
dc.contributor.authorI-Move Primary Care Study Team, null
dc.identifier.citationEuro Surveill. 2019 Nov;24(48).es_ES
dc.description.abstractIntroductionInfluenza A(H3N2) clades 3C.2a and 3C.3a co-circulated in Europe in 2018/19. Immunological imprinting by first childhood influenza infection may induce future birth cohort differences in vaccine effectiveness (VE).AimThe I-MOVE multicentre primary care test-negative study assessed 2018/19 influenza A(H3N2) VE by age and genetic subgroups to explore VE by birth cohort.MethodsWe measured VE against influenza A(H3N2) and (sub)clades. We stratified VE by usual age groups (0-14, 15-64, ≥ 65-years). To assess the imprint-regulated effect of vaccine (I-REV) hypothesis, we further stratified the middle-aged group, notably including 32-54-year-olds (1964-86) sharing potential childhood imprinting to serine at haemagglutinin position 159.ResultsInfluenza A(H3N2) VE among all ages was -1% (95% confidence interval (CI): -24 to 18) and 46% (95% CI: 8-68), -26% (95% CI: -66 to 4) and 20% (95% CI: -20 to 46) among 0-14, 15-64 and ≥ 65-year-olds, respectively. Among 15-64-year-olds, VE against clades 3C.2a1b and 3C.3a was 15% (95% CI: -34 to 50) and -74% (95% CI: -259 to 16), respectively. VE was -18% (95% CI: -140 to 41), -53% (95% CI: -131 to -2) and -12% (95% CI: -74 to 28) among 15-31-year-olds (1987-2003), 32-54-year-olds (1964-86) and 55-64-year-olds (1954-63), respectively.DiscussionThe lowest 2018/19 influenza A(H3N2) VE was against clade 3C.3a and among those born 1964-86, corresponding to the I-REV hypothesis. The low influenza A(H3N2) VE in 15-64-year-olds and the public health impact of the I-REV hypothesis warrant further study.es_ES
dc.description.sponsorshipWe thank Dr Danuta Skowronski for detailed explanation of the I-REV hypothesis, shared discussions and helpful comments on our manuscript. We thank Pernille Jorgensen (WHO/Europe) for her continued support for the I-MOVE network over the years. We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID's EpiFlu Database used for this study. All submitters of data may be contacted directly via the GISAID websites_ES
dc.publisherEuropean Centre for Disease Prevention and Controles_ES
dc.relation.isversionofPublisher's versiones_ES
dc.subjectbirth cohortses_ES
dc.subjectmulticentre studyes_ES
dc.subjectvaccine effectivenesses_ES
dc.titleLow 2018/19 vaccine effectiveness against influenza A(H3N2) among 15-64-year-olds in Europe: exploration by birth cohortes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.journalEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletines_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemologíaes_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional